1. Interactive Effects of Perinatal BPA or DES and Adult Testosterone and Estradiol Exposure on Adult Urethral Obstruction and Bladder, Kidney, and Prostate Pathology in Male Mice.
- Author
-
Taylor JA, Jones MB, Besch-Williford CL, Berendzen AF, Ricke WA, and S Vom Saal F
- Subjects
- Animals, Biological Assay, Female, Hydronephrosis, Kidney pathology, Male, Mice, Organ Size, Pregnancy, Pregnancy, Animal, Prenatal Exposure Delayed Effects, Prostate pathology, Prostatic Hyperplasia pathology, Prostatitis pathology, Urinary Bladder pathology, Benzhydryl Compounds toxicity, Diethylstilbestrol toxicity, Estradiol pharmacology, Phenols toxicity, Testosterone pharmacology, Urethral Obstruction physiopathology
- Abstract
Obstructive voiding disorder (OVD) occurs during aging in men and is often, but not always, associated with increased prostate size, due to benign prostatic hyperplasia (BPH), prostatitis, or prostate cancer. Estrogens are known to impact the development of both OVD and prostate diseases, either during early urogenital tract development in fetal-neonatal life or later in adulthood. To examine the potential interaction between developmental and adult estrogen exposure on the adult urogenital tract, male CD-1 mice were perinatally exposed to bisphenol A (BPA), diethylstilbestrol (DES) as a positive control, or vehicle negative control, and in adulthood were treated for 4 months with Silastic capsules containing testosterone and estradiol (T+E2) or empty capsules. Animals exposed to BPA or DES during perinatal development were more likely than negative controls to have urine flow/kidney problems and enlarged bladders, as well as enlarged prostates. OVD in adult T+E2-treated perinatal BPA and DES animals was associated with dorsal prostate hyperplasia and prostatitis. The results demonstrate a relationship between elevated exogenous estrogen levels during urogenital system development and elevated estradiol in adulthood and OVD in male mice. These findings support the two-hit hypothesis for the development of OVD and prostate diseases.
- Published
- 2020
- Full Text
- View/download PDF